380 related articles for article (PubMed ID: 20041476)
1. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy.
Dell'Osso B; Buoli M; Baldwin DS; Altamura AC
Hum Psychopharmacol; 2010 Jan; 25(1):17-29. PubMed ID: 20041476
[TBL] [Abstract][Full Text] [Related]
2. Qualitative review of SNRIs in anxiety.
Silverstone PH
J Clin Psychiatry; 2004; 65 Suppl 17():19-28. PubMed ID: 15600378
[TBL] [Abstract][Full Text] [Related]
3. Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders.
Jakubovski E; Johnson JA; Nasir M; Müller-Vahl K; Bloch MH
Depress Anxiety; 2019 Mar; 36(3):198-212. PubMed ID: 30479005
[TBL] [Abstract][Full Text] [Related]
4. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
5. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
Ishigooka J
Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
[TBL] [Abstract][Full Text] [Related]
6. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
[TBL] [Abstract][Full Text] [Related]
7. Emerging anxiolytics.
Pillay NS; Stein DJ
Expert Opin Emerg Drugs; 2007 Nov; 12(4):541-54. PubMed ID: 17979598
[TBL] [Abstract][Full Text] [Related]
8. Trajectory and magnitude of response in adults with anxiety disorders: a Bayesian hierarchical modeling meta-analysis of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and benzodiazepines.
Mendez EM; Mills JA; Suresh V; Stimpfl JN; Strawn JR
CNS Spectr; 2024 Jun; 29(3):187-196. PubMed ID: 38523533
[TBL] [Abstract][Full Text] [Related]
9. Future directions for serotonin and antidepressants.
Artigas F
ACS Chem Neurosci; 2013 Jan; 4(1):5-8. PubMed ID: 23336036
[TBL] [Abstract][Full Text] [Related]
10. New developments in the neurobiological basis of anxiety disorders.
Gorman JM; Hirschfeld RM; Ninan PT
Psychopharmacol Bull; 2002; 36 Suppl 2():49-67. PubMed ID: 12490823
[TBL] [Abstract][Full Text] [Related]
11. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression.
Gorman JM; Kent JM
J Clin Psychiatry; 1999; 60 Suppl 4():33-8; discussion 39. PubMed ID: 10086481
[TBL] [Abstract][Full Text] [Related]
12. The impact of antidepressants on seizure frequency and depressive and anxiety disorders of patients with epilepsy: Is it worth investigating?
Ribot R; Ouyang B; Kanner AM
Epilepsy Behav; 2017 May; 70(Pt A):5-9. PubMed ID: 28407526
[TBL] [Abstract][Full Text] [Related]
13. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?
Shelton CI
J Clin Psychiatry; 2004; 65 Suppl 17():29-33. PubMed ID: 15600379
[TBL] [Abstract][Full Text] [Related]
14. Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy.
Humble M
Acta Psychiatr Scand Suppl; 2000; 402():28-36. PubMed ID: 10901156
[TBL] [Abstract][Full Text] [Related]
15. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of concomitant use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release.
Peniston JH; Hu X; Potts SL; Wieman MS; Turk DC
Postgrad Med; 2012 Mar; 124(2):114-22. PubMed ID: 22437221
[TBL] [Abstract][Full Text] [Related]
17. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies.
Frazer A
J Clin Psychiatry; 2001; 62 Suppl 12():16-23. PubMed ID: 11430614
[TBL] [Abstract][Full Text] [Related]
18. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
[TBL] [Abstract][Full Text] [Related]
19. The mixed amphetamine salt extended release (Adderall XR, Max-XR) as an adjunctive to SSRIS or SNRIS in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety: an open-label study.
Gabriel A
Atten Defic Hyperact Disord; 2010 Jun; 2(2):87-92. PubMed ID: 21432593
[TBL] [Abstract][Full Text] [Related]
20. The dual-action hypothesis: does pharmacology matter?
Shelton RC
J Clin Psychiatry; 2004; 65 Suppl 17():5-10. PubMed ID: 15600376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
